VASCEPA® (Icosapent Ethyl)
Severe Hypertriglyceridemia (≥500 mg/dL)
Key Facts
About Amarin Corporation
Amarin Corporation is a global biopharmaceutical company with a mission to improve cardiovascular health through innovative science. Its primary achievement is the development and commercialization of VASCEPA® (icosapent ethyl), a drug with a landmark cardiovascular outcomes trial (REDUCE-IT) that demonstrated significant risk reduction in major adverse cardiovascular events. The company's strategic direction involves defending and expanding the market for VASCEPA, while also exploring its potential in other indications and advancing its pipeline. Amarin faces the challenge of navigating generic competition and payer reimbursement dynamics while seeking to maximize the global value of its core asset.
View full company profileAbout Amarin Corporation
Amarin Corporation is a global biopharmaceutical company with a mission to improve cardiovascular health through innovative science. Its primary achievement is the development and commercialization of VASCEPA® (icosapent ethyl), a drug with a landmark cardiovascular outcomes trial (REDUCE-IT) that demonstrated significant risk reduction in major adverse cardiovascular events. The company's strategic direction involves defending and expanding the market for VASCEPA, while also exploring its potential in other indications and advancing its pipeline. Amarin faces the challenge of navigating generic competition and payer reimbursement dynamics while seeking to maximize the global value of its core asset.
View full company profile